Who are beta-1,3-glucan's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/beta-1-3-glucan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

beta-1,3-glucan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

beta-1,3-glucan (beta-1,3-glucan) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunostimulant / Biological response modifier. Area: Immunology / Oncology.

marketed Immunostimulant / Biological response modifier Dectin-1 (and other pattern recognition receptors) Immunology / Oncology Small molecule Live · refreshed every 30 min

Target snapshot

beta-1,3-glucan (beta-1,3-glucan) — Meiji University of Oriental Medicine. Beta-1,3-glucan is a polysaccharide that activates innate immune cells, particularly macrophages and neutrophils, to enhance immune response and promote anti-tumor or anti-infection activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
beta-1,3-glucan TARGET	beta-1,3-glucan	Meiji University of Oriental Medicine	marketed	Immunostimulant / Biological response modifier	Dectin-1 (and other pattern recognition receptors)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunostimulant / Biological response modifier class)

Meiji University of Oriental Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). beta-1,3-glucan — Competitive Intelligence Brief. https://druglandscape.com/ci/beta-1-3-glucan. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing